An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
Trial Status: active
The purpose of this study is to determine if vimseltinib is safe, tolerable and works
effectively to treat adults with active moderate to severe cGVHD. Participants will be
treated with vimseltinib in 28-day treatment cycles for approximately 2 years.
Inclusion Criteria
Must be allogeneic hematopoietic stem cell transplant (HSCT) recipients with moderate to severe cGVHD requiring systemic immune suppression. a. May have persistent active GVHD (aGVHD) and chronic GVHD (cGVHD) manifestations (overlap syndrome).
Participants with active cGVHD who have received and failed at least 2 prior lines of systemic therapy.
Stable dose of systemic corticosteroids is permitted but not required. If being taken, participants should be on a stable dose of corticosteroids for at least 2 weeks prior to starting study drug treatment.
Adequate organ and bone marrow functions.
Participants of reproductive potential agree to follow the contraception requirements.
Karnofsky Performance Scale (KPS) of ≥60.
Exclusion Criteria
Has aGVHD without manifestations of cGVHD.
Prior use of colony-stimulating factor 1 receptor (CSF1R) inhibitor for cGVHD.
History or other evidence of severe illness, uncontrolled infection, or any other conditions that would make the participant unsuitable for the study.
History of malignancy except for:
Underlying malignancy for which the transplant was performed
Malignancy treated with curative intent and with no evidence of active disease present for more than 3 years prior to enrollment and felt to be at low risk for recurrence.
Malabsorption syndrome or other illness that could affect oral absorption.
Additional locations may be listed on ClinicalTrials.gov for NCT06619561.
